Internal Medicine
Partner With Us
Advertisement
Conexiant chevron_right Internal Medicine chevron_right First Cell Based Gene Therapy Approved
From the Journals

First Cell-Based Gene Therapy Approved

FDA approves Zevaskyn (pz-cel), a cell-based gene therapy, for the treatment of recessive dystrophic epidermolysis bullosa.

Reuters
Full Article Summary Notecard
  1. Zevaskyn, a cell-based gene therapy, has been FDA approved for recessive dystrophic epidermolysis bullosa (RDEB).
  2. It addresses the fragility of skin, blistering, and nonhealing wounds caused by genetic variants in the COL7A1 gene.
  3. Zevaskyn anticipates commercial availability in the third quarter of 2025.
  4. The therapy results in significant wound healing and pain reduction.
  5. Concurrent use of Vyjuvek and Zevaskyn may improve overall RDEB management.

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.